One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

Clin Infect Dis. 2020 Jan 16;70(3):521-524. doi: 10.1093/cid/ciz454.

Abstract

In Malawi, 236 participants from the Advancing Cryptococcal Meningitis Treatment for Africa trial were followed for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericin B plus flucytosine was associated with the lowest 1 year mortality (27.5% [95% confidence interval, 16.3 to 44.1]).

Keywords: HIV; Malawi; cryptococcal meningitis; long-term follow-up; treatment.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / therapeutic use
  • Fluconazole
  • Flucytosine
  • Humans
  • Malawi / epidemiology
  • Meningitis, Cryptococcal* / drug therapy
  • Meningitis, Cryptococcal* / epidemiology

Substances

  • Antifungal Agents
  • Fluconazole
  • Flucytosine